asco - PowerPoint Presentations and PDF Documents

Oncological Surgyery : 1. ASCO:

by queenie

Lyman. GH, . Bohlke. K, . Khorana. AA, et al. ....

Year in Review Prostate Cancer

by faith

Emmanuel . S . Antonarakis. , MD. Professor of Onc...

TRK fusion-positive cancer highlights from ASCO 2022

by joanne

Prof. David S. Hong. Medical Oncologist. MD Anders...

Updates in the systemic treatment for lung

by madeline

cancer: Immunotherapy. Oscar Arrieta MD. Thoracic....

Checkpoint inhibitors for

by paisley

NSCLC. An update. Solange Peters, MD-PhD. Oncology...

Ezra W Cohen University of California, San Diego

by natalia-silvester

Ezra W Cohen University of California, San Diego...

mCODE Community of Practice Monthly Meeting

by jocelyn

Chairs – Rob Dingwell & Zeshan Rajput. Suppo...

Jchem applications in Medchem

by StarsAndStripes

Prediction. . and. . Data Sorting. Zhengtao. Li...

Presented at the American Society of Clinical Oncology ASCO Annual Mee

by eliza

8 2021Patientswithhigh-doselymphodepletionCohort2w...

Immunotherapy – the good news and the bad

by medshair

Associate Professor Philip Beale. Chair ANZGOG Cli...

Immunotherapy – the good news and the bad

by warlikebikers

Associate Professor Philip Beale. Chair ANZGOG Cli...

ASCO 2012 Review Gynecologic Cancer

by welnews

Nelson Teng, M.D., Ph.D.. Director, Gynecologic On...

Behandeling van het recidief ovariumcarcinoom

by sandsomber

Ignace Vergote MD PhD FACS FSPS. Chairman, Leuven ...

Best of ASCO GU Session Sandy Srinivas.MD

by experimentgoogle

Stanford University. Outline. Abstract #4. :. . I...

Ovarian cancer with update from ASCO 2013

by karlyn-bohler

Siew. . wei. . wong. Oncology registrar. Epidem...

ASCO 2019 NSCLC - PARP & Chemotherapy

by mitsue-stanley

ASCO 2019 NSCLC - PARP & Chemotherapy REF Stu...

Search Results for ''